All Stories
- Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods
Article
- Twenty-Four–Hour Measures of Heart Rate–Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment
Article
- Reference Limits for Outlier Analyses in Randomized Clinical Trials
Article
- Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
- Systematic Decrements in QTc between the First and Second Day of Contiguous Daily ECG Recordings under Controlled Conditions
Article
- Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development
Article
- Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development
- Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
- Letter to the Editor
- Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
Article
- Fluoxetine and Adult Suicidality Revisited
- Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
Article
- All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics
- Early Symptomatic Worsening During Treatment With Fluoxetine in Major Depressive Disorder
Article
- Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes
Article
- Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis
- Is Quality of Life Among Minimally Symptomatic Patients With Schizophrenia Better Following Withdrawal or Continuation of Antipsychotic Treatment?
- Efficacy and Safety of Oral Tadalafil in the Treatment of Men in Canada with Erectile Dysfunction: A Randomized, Double‐Blind, Parallel, Placebo‐Controlled Clinical Trial
- The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval
- Tadalafil Improved Erectile Function at Twenty-Four and Thirty-Six Hours After Dosing in Men With Erectile Dysfunction: US Trial
- Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5—sildenafil, tadalafil, and vardenafil
- A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil
- A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
- Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive Hormones
- An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients With Schizophrenia During Olanzapine Clinical Trials
- Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
- When Should a Trial of Fluoxetine for Major Depression Be Declared Failed?
- Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
Article
- Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia
- Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
- Fluoxetine and Norfluoxetine Plasma Levels After Discontinuing Fluoxetine Therapy
- Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis
- Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial
- Hematologic Reference Ranges in a Population of Patients with Schizophrenia
- Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis
- Efficacy, Adverse Events, and Treatment Discontinuations in Fluoxetine Clinical Studies of Major Depression
- Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression
- Fluoxetine efficacy in menopausal women with and without estrogen replacement
- Plasma Olanzapine and Clinical Response
- Blood Pressure Changes During Short-Term Fluoxetine Treatment
- Response to Letter of Professor Tim Lambert
- Olanzapine
- Olanzapine versus haloperidol in the treatment of schizoaffective disorder
- Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
- Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
- Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
- Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment
- A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia
- Safety of Abrupt Discontinuation of Fluoxetine
- Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
- Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo
- Olanzapine Versus Placebo and Haloperidol: Quality of Life and Efficacy Results of the North American Double-Blind Trial
- Suicidality with Fluoxetine
- Olanzapine Plasma Concentrations and Clinical Response in Acutely Ill Schizophrenic Patients
- Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
- Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders
- Fluoxetine in Medically Stable, Depressed Geriatric Patients
- Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
- The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
- Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study
- Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia
- Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
- Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
- Fluoxetine in Depressed Patients on Dialysis
- Letter to the editors
- Olanzapine VS. chlorpromazine in therapy-refractory schizophrenia
- Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
- Olanzapine versus Placebo and Haloperidol
- Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function
- Absence of a Relationship Between Adverse Events and Suicidality During Pharmacotherapy for Depression
- Fluoxetine
- Fluoxetine not associated with increased aggression in controlled clinical trials
- Fluoxetine versus amitriptyline in the treatment of major depression
- The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine
- Fluoxetine
- Reply to Dr. Friedman
- Fluoxetine: a review of receptor and functional effects and their clinical implications
- Fluoxetine: no association with suicidality in obsessive-compulsive disorder
- Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
- Fluoxetine Mechanism of Action
- High-Dose Fluoxetine
- Fluoxetine in tricyclic refractory major depressive disorder
- Correction to ‘Fluoxetine Overdose: A Case Report’
- TSH response to TRH and haloperidol response latency in psychoses
- A General Learning Theory and its Application to Schema Abstraction1